https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-07-31 / J Clin Oncol 32, 2014 (suppl 4; abstr 189)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-07-31 / J Clin Oncol 32, 2014 (suppl 4; abstr 189)2014-07-31 12:07:522019-09-30 11:21:53Response of blood flow to hyperthermia in human prostate tumors: Opportunities for enhanced radiation effect and drug delivery.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr 3095)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr 3095)2014-06-01 00:00:002014-06-01 00:00:00Combined chemoimmunotherapy of castrate-resistant prostate cancer with dendritic-cell based vaccine DCVAC/Pca.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr 3099)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr 3099)2014-06-01 00:00:002014-06-01 00:00:00Cancer immunotherapy of patients with the biochemical relapse of the prostate cancer using dendritic cell-based vaccine DCVAC/PCa.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-01-23 / J. Virol. 2013 Apr;87(7):3792-800
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-01-23 / J. Virol. 2013 Apr;87(7):3792-8002013-01-23 00:00:002013-01-23 00:00:00Prostate-specific antigen-retargeted recombinant newcastle disease virus for prostate cancer virotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-05-29 / Nat Rev Urol 2012 May;9(7):376-85
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-05-29 / Nat Rev Urol 2012 May;9(7):376-852012-05-29 00:00:002019-02-15 08:53:11Cancer immunotherapy: a paradigm shift for prostate cancer treatment
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-05-01 / Curr Opin Urol 2012 May;22(3):197-202
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-05-01 / Curr Opin Urol 2012 May;22(3):197-2022012-05-01 00:00:002019-02-15 09:23:55Current status of immunological approaches for the treatment of prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-03-01 / Expert Rev Vaccines 2012 Mar;11(3):287-302
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-03-01 / Expert Rev Vaccines 2012 Mar;11(3):287-3022012-03-01 00:00:002019-02-15 08:52:44Prostate cancer vaccines: moving therapeutic vaccination forward in the post-Provenge era
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-01-01 / Urologe A 2012 Jan;51(1):44-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-01-01 / Urologe A 2012 Jan;51(1):44-92012-01-01 00:00:002019-02-15 08:52:47[Prostate carcinoma: vaccination as a new option for treatment]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-11-26 / Vaccine 2012 Jun;30(29):4394-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-11-26 / Vaccine 2012 Jun;30(29):4394-72011-11-26 00:00:002019-02-15 08:52:45Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-10-03 / Eur. Urol. 2012 Feb;61(2):290-306
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-10-03 / Eur. Urol. 2012 Feb;61(2):290-3062011-10-03 00:00:002019-02-15 08:52:46Current vaccination strategies for prostate cancer
